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Helical Peptoid Mimics
of Lung Surfactant Protein C
N-substituted glycine backbone and its absence of hy-
drogen bond donors, oligopeptoids are able to adopt
stable, chiral helices when substituted with -chiral, ste-
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Northwestern University rically bulky side chains [9, 10]. Their ability to form
stable helices makes peptoids an excellent candidate2145 Sheridan Road, Room E136
Evanston, Illinois 60208 for mimicry of bioactive molecules that rely on helical
structure for proper function.2 Department of Chemistry
The Institute for Biophysical Dynamics and There is a clinical need for good mimics of the hy-
drophobic human lung surfactant proteins (SP), whichThe James Franck Institute
University of Chicago perform critical functions in lung surfactant (LS) replace-
ments used to treat respiratory distress syndrome (RDS)5735 Ellis Avenue
Chicago, Illinois 60637 in premature infants. LS is a complex mixture of lipids
and surfactant proteins that dramatically reduces alveo-
lar surface tension and the work of breathing [11]. Ani-
mal-derived surfactants are widely used and show goodSummary
efficacy in rescuing premature infants who suffer from
respiratory distress due to a lack of surfactant at birthAmong the families of peptidomimetic foldamers under
development as novel biomaterials and therapeutics, [11]; however, this approach raises some safety con-
cerns [12]. In recent years, there has been increasingpoly-N-substituted glycines (peptoids) with -chiral
side chains are of particular interest for their ability to interest in the development of a synthetic, biomimetic
LS replacement that functions as well as the animal-adopt stable, helical secondary structure in organic
and aqueous solution. Here, we show that a peptoid derived material [13]. The success of this endeavor re-
quires an understanding of the roles of the lipid and22-mer with a biomimetic sequence of side chains and
an amphipathic, helical secondary structure acts as surfactant protein components of natural LS [11, 13]
and an ability to closely mimic their surface-active prop-an excellent mimic of surfactant protein C (SP-C), a
small protein that plays an important role in surfactant erties. Natural LS is composed primarily of dipalmitoyl-
phosphatidylcholine (DPPC), unsaturated phosphatidyl-replacement therapy for the treatment of neonatal re-
spiratory distress syndrome. When integrated into a cholines (PC), unsaturated phosphatidylglycerol (PG),
palmitic acid (PA), and surfactant proteins (SP-A, B, C,lipid film, the helical peptoid SP mimic captures the
essential surface-active behaviors of the natural pro- and D), along with other minor lipid components and
cholesterol [11]. Although SP comprise 10% of LS bytein. This work provides an example of how an abiolog-
ical oligomer that closely mimics both the hydropho- weight [11], surfactant replacements composed of lipids
alone and lacking SP have been shown to be ineffectivebic/polar sequence patterning and the fold of a natural
protein can also mimic its biophysical function. in capturing the requisite properties of LS for therapeutic
purposes [14]. Researchers have shown that in particu-
lar, the hydrophobic, amphipathic proteins SP-B andIntroduction
SP-C are critical for the proper biophysical functioning
of LS, due to their ability to enhance the adsorption andRecent research has been directed toward the creation
of nonnatural, sequence-specific oligomers with bio- respreading of the lipid components at the air-liquid
interface [15]. With this realization, several groups haveinspired structures that capture both the amino acid
sequence patterning and three-dimensional folds of nat- developed synthetic peptide or recombinant protein ver-
sions of SP-B and SP-C and investigated their abilityural proteins [1–3]. Such biomimetic oligomers may
eventually serve as useful peptide replacements with to enhance the performance of surfactant formulations
composed of synthetic lipids [16–20]. These mimics arebetter in vivo stability than the natural molecules. The
currently being used to investigate the mechanisms ofhypothesis is that compounds with bioinspired struc-
action of SP-B and SP-C [21–24]; however, it is stilltures may also offer good functional mimicry. Several
not conclusively understood whether these two proteinsdifferent families of abiological oligomers have been
work synergistically or individually to affect and enhancesynthesized [2, 3] and proposed as novel mimics of
the biophysical surface activity of the natural lipidnatural molecules such as magainin, a helical, amphi-
mixture.pathic antimicrobial peptide [4–6]. One such family of
SP-C is the smaller and simpler of the two amphipathicmolecules is the poly-N-substituted glycines or “pep-
LS proteins, at just 35 monomers in length. The three-toids,” which have close structural similarity to peptides
dimensional structure of human SP-C has been solvedbut are essentially invulnerable to protease degradation
by 2D NMR in methanol solution and is predominantly[7] and hence are biostable and less prone to immune
helical [25]. In its correctly folded form, this amphipathicsystem recognition [8]. Despite the achirality of the
protein contains an  helix 37 A˚ long comprising resi-
dues 9–34. Within this region is a 26 A˚ long, valyl-rich*Correspondence: a-barron@northwestern.edu
stretch of hydrophobic amino acids. FTIR studies have3 Also, by courtesy, Departments of Chemistry and Biomedical Engi-
neering, Northwestern University shown that the SP-C  helix orients in a transbilayer
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Figure 1. SP-C Peptide and Peptoid Sequence and Structure
(A) A modified SP-C peptide sequence.
(B) The chemical structure of a peptoid 22-mer created as a mimic of (A).
(C) CD spectra of the peptoid-based SP-C mimic in comparison to that of the SP-C peptide shown in (A).
(D) A molecular model of the SP-C peptoid structure. The helical, hydrophobic region of the peptoid is displayed in green, the charged residues
(NLys and NArg) are shown in red, and the flexible, achiral amino-terminal region is shown in blue.
orientation in a fluid lipid film, where the helical region LS replacement we have created offers an intriguing and
potentially advantageous alternative to animal-derivedinteracts hydrophobically with lipid acyl chains [26]. Two
adjacent, positively charged residues at positions 11 and peptide-based surfactants.
and 12 interact with anionic phospholipid head groups
and promote SP binding to the monolayer or bilayer by
ionic interactions [27]. Cysteine residues 5 and 6 are Results and Discussion
posttranslationally modified with palmitoyl groups, the
function and importance of which are debated in the Various peptide mimics of SP-C have been created and
have shown promise as spreading agents for surfactantliterature [28–32]. In an LS film, SP-C promotes phos-
pholipid insertion into the air-liquid interface [24] and lipids [18–20, 34, 35]. Due to its extreme hydrophobicity
and strong tendency to misfold and aggregate in thethereby enhances the rate of lipid adsorption [30, 31]
as well as the respreading of the alveolar film upon absence of phospholipids [36], SP-C peptide with the
natural human sequence is very challenging to synthe-inhalation [33].
Here, we show that a nonnatural peptoid with a spe- size and purify in good yield. Therefore, researchers
have identified alternative peptide sequences, closelycific, 22-monomer sequence and an amphipathic, heli-
cal structure serves as an excellent mimic of lung surfac- related to that of human SP-C, comprising amino acid
substitutions that reduce the peptide’s tendency to ag-tant protein C. When integrated into a lipid film, the
peptoid analog of SP-C captures, to a significant extent, gregate in solution without appearing to compromise
its activity [36, 37]. After finding a protein with the naturalthe unique surface-active behaviors of the natural pro-
tein. These results show that a nonnatural oligomer that human sequence very difficult to work with, we chose
to use a modified polypeptide for comparison to ourmimics both the hydrophobic/polar sequence patterning
and the folded structure of a natural protein can also peptide mimic, following the previous work cited above.
The primary structure of the modified polypeptide [SP-Cmimic that protein’s biophysical functioning. The novel
Peptoid Mimics of Lung Surfactant Protein C
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Figure 3. Langmuir-Wilhelmy Surface Balance Isotherms
Surface pressure ()-area isotherms obtained for a lipid mixture
alone and with 10% (w/w) of either SP-C peptide or SP-C peptoid
added. Results indicate that the addition of the SP-C mimics engen-
ders biomimetic surface activity, as indicated by liftoff at a higher
molecular area and the introduction of a biomimetic plateau.
residues/turn, and a pitch of 6 A˚ [9, 10, 38]. Taking
into account the differences in helical pitch between a
peptide  helix and a peptoid helix, we estimated that
14 Nspe residues are sufficient to mimic the length of
the hydrophobic helical stretch in SP-C. The 8-residue
amino-terminal stretch of the SP-C peptoid is composed
of achiral residues, most of which have side chain struc-
tures similar to the amino acids found in human SP-C
(5–12) and conserve the basic patterning of charged and
polar residues in the natural peptide. We substituted
Figure 2. Pulsating Bubble Surfactometry Results N-phenylmethyl (Npm) monomers for the palmitoylated
Static and dynamic characterization of surfactant film properties cysteines found at positions 5 and 6 in the human se-
performed on a pulsating bubble surfactometer (PBS).
quence (similar to a natural, phenylalanine substitution(A) Adsorption surface tension  versus time t for lipids alone and
found at position 6 in canine SP-C [39]) and the histidinewith addition of either SP-C peptide or SP-C peptoid. The presence
found at position 9 in natural, human SP-C.of the SP-C mimics significantly improves adsorption kinetics.
(B) Surface tension versus area (compression and expansion loops The peptoid oligomer shown in Figure 1B exhibits
obtained by cycling at a frequency of 20 cycles/min) of a pure lipid circular dichroism (CD) spectral features in organic solu-
mixture, a lipid mixture with SP-C peptide, and a lipid mixture with tion that are similar to that of SP-C peptide (Val→Leu,
SP-C peptoid. The addition of either the SP-C peptide or the SP-C
Cys→Ser) and are characteristic of a stable helical struc-peptoid alters the loop shape so that less area compression is
ture, with an intense maximum at 192 nm and doublerequired to obtain low surface tension, relative to the observation
minima at 205 nm and 220 nm (Figure 1C) [40]. Thesefor the pure lipid mixture. Additionally, the maximum surface tension
is substantially reduced upon addition of either mimic. are the characteristic spectral signatures of a helical
structure with highly ordered backbone amide bonds
[9]. Hence, the SP-C peptoid satisfies one of the major
structural criteria—helicity—believed to be important for(Val→Leu, Cys→Ser)] used in these studies is shown in
Figure 1A. mimicry of the natural protein. An idealized molecular
model of the SP-C peptoid we designed is shown inA peptoid oligomer was designed to capture both
the amphipathic and helical characteristics of the SP-C Figure 1D, where the hydrophobic, helical region is shown
in green, the two positively charged residues in red, andprotein. The chemical structure of the peptoid mimic we
created, a 22-mer (“SP-C peptoid”), is shown in Figure the remainder of the amino-terminal region in blue.
The biophysical film characteristics that are important1B. The SP-C peptoid mimics the patterning of hy-
drophobic and polar side chain moieties in a truncated to capture with an LS replacement include the abilities
of natural LS to adsorb rapidly to an air-water interface,version of SP-C, including residues 5–32 of the natural
35-mer, which has been shown to have comparable to reduce and control surface tension as a function of
surface area, and to respread quickly upon surface expan-activity to native SP-C [18]. Oligopeptoids comprised of
N-(S)-1-phenylethyl (Nspe) monomers, with their bulky, sion [11]. Based on a previous report [41], we chose an
optimized lipid formulation comprised of DPPC:POPG:PAaromatic side chain moieties, adopt particularly stable
polyproline type I-like helices with cis-amide bonds, 3 (68:22:9, by weight) that has been shown to closely
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Figure 4. Fluorescence Microscopy Images
Fluorescence microscope images of surfac-
tant film morphology on the LWSB. Images
correspond to surface pressures of 25 mN/
m (left) and 40 mN/m (right) for a pure lipid
mixture (A and D), a lipid/SP-C peptide mix-
ture (B and E), and a lipid/SP-C peptoid mix-
ture (C and F).
mimic the behaviors of the lipid portion of LS [11]. The As a complement to the PBS experiments, a home-
built Langmuir-Wilhelmy surface balance (LWSB) [43]performance of this lipid mixture alone and with the
addition of 10% (w/w) SP-C peptide or peptoid was was used to evaluate the surface activity of these bio-
mimetic surfactant formulations. Previous studies havecharacterized using a pulsating bubble surfactometer
(PBS) at 37C. Figure 2A compares the adsorption sur- shown that LS replacements that exhibit good biophysi-
cal activity on a LWSB also generally perform well in inface tension (ads) as a function of time for the three
surfactant formulations, obtained by running the PBS in vivo tests using animal or animal lung models of RDS
[44, 45]. Surface pressure-area (-A) isotherms werestatic mode, i.e., without cycling bubble area. In the
absence of SP mimics, the lipid mixture fails to reach obtained at 37C for the pure lipid mixture, the lipid/
SP-C peptide mixture, and the lipid/SP-C peptoid mix-ads lower than 30 dynes/cm even after 15 min (natural,
animal-derived LS reaches ads20–25 dynes/cm within ture (Figure 3). We find that the addition of either the
SP-C peptide or the SP-C peptoid results in the liftoffa few seconds [42]). We find that the addition of the
SP-C peptide significantly accelerates the kinetics of of the isotherm at a higher molecular area, demonstra-
ting that both the surface-active peptide and the peptoidlipid adsorption to the interface, allowing the film to
reach ads 25 dynes/cm within 20 s. With the addition rapidly take physical positions at the interface. We also
observe the occurrence of a pronounced plateau in theof the helical SP-C peptoid, we observe similarly accel-
erated kinetics of adsorption. isotherm for both the peptide and the peptoid SP-C
mimics. This plateau is observed for natural LS and hasIt is also important for an LS replacement to reduce
and control surface tension, , as surface area is cycli- been postulated to coincide with the removal of lipids
and proteins from the monolayer to a surface-associ-cally expanded and compressed. Figure 2B shows a
plot, obtained on the PBS in a dynamic mode, showing ated surfactant reservoir near the interface, resulting in
a multilayered film [46, 47]. The presence of this reservoir as a function of bubble surface area for a lipid mixture,
a lipid/SP-C peptide mixture, and a lipid/SP-C peptoid offers an explanation for how natural SPs interact with
lipids to provide low surface tension in the surfactantmixture. The compression-expansion loop for the pure
lipid mixture shows that a significant degree of film com- film upon compression (exhalation) and yet respread
rapidly on film expansion (inhalation), an activity that ispression is required to achieve a minimum  of 20 dynes/
cm, whereas a relatively high maximum  of 46 dynes/ also important for stabilizing the alveolar network of the
lung [46, 48, 49]. The -A isotherms obtained with thecm is reached upon film expansion. The addition of the
SP-C peptide substantially reduces the degree of film SP-C peptoid are similar to those obtained with the SP-C
peptide, but show a somewhat later liftoff and a lesscompression required to achieve a much lower minimum
 of 10 dynes/cm and also allows the attainment of a pronounced plateau. However, the substantial similarity
observed in the isotherms suggests that the SP-C pep-much lower maximum  of 30 dynes/cm. These sur-
face-active behaviors are unique to lung surfactant mix- toid captures many of the critical surface-active behav-
iors of SP-C peptide.tures and are due to the interaction of surfactant proteins
with phospholipids in the film [42]. Interestingly, a lipid To further compare the surface-active properties of
the lipid mixture with and without the peptide and pep-film spiked with the SP-C peptoid displays a compres-
sion-expansion loop that is highly similar to that of the toid SP-C mimics, fluorescence microscopy (FM) was
used in conjunction with the LWSB to study the surfaceSP-C peptide. Hence, it appears that this completely
nonnatural peptoid oligomer can capture the essential morphology of lipid, lipid/peptide, and lipid/peptoid
films. Figure 4 displays FM images of surfactant filmbiophysical behaviors of SP-C peptide in a lipid film.
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morphology at surface pressures of 25 mN/m (left) and layers. Optimization of this formulation for an even
closer mimicry of calf lung surfactant is ongoing. For40 mN/m (right) for the lipid mixture (Figures 4A and 4D),
lipid/peptide mixture (Figures 4B and 4E), and a lipid/ example, this biomimetic LS formulation lacks a mimic
of SP-B, which has also been shown to be importantpeptoid mixture (Figures 4C and 4F). The FM image for
the lipid mixture reveals dark, flower-shaped domains for LS functioning [15]; peptoid-based SP-B mimics
are currently under development in our lab. Furtherthat correspond to a liquid-condensed (LC) phase (Fig-
ure 4A). Upon surface compression, these domains investigations, including animal studies, will allow us
to evaluate the efficacy and safety of peptoid-con-greatly increase in size and area fraction, while the ex-
tent of the lighter liquid-expanded (LE) region is substan- taining surfactants for in vivo application.
tially reduced (Figure 4D). A “dark” film like that shown
Experimental Proceduresin Figure 4D is enriched in DPPC and does not respread
well upon subsequent surface expansion [50]. In com-
Materialsparison, the images taken with added SP-C peptide
Peptide and peptoid synthesis reagents were purchased from Ap-
show that the peptide interacts with the lipids to retain plied Biosystems (Foster City, CA) or Sigma-Aldrich (Milwaukee,
the fluidity of the film upon compression, as evidenced WI). Fmoc-protected amino acids, resins, and t-Boc were purchased
from NovaBiochem (San Diego, CA), PMC was purchased fromby the larger extent of light LE regions and the dramatic
Omega Chemical (Quebec, Canada), and primary amines were pur-decrease in LC domain size in Figure 4E. This increase
chased from Sigma-Aldrich. HPLC-grade solvents were purchasedin fluidity allows better respreading of surfactant upon
from Fisher Scientific (Pittsburgh, PA). DPPC, POPG, and NBD-PCsubsequent surface compressions. This important be-
were purchased from Avanti Polar Lipids (Alabaster, AL), and PA
havior is partially mimicked by the addition of SP-C was purchased from Sigma-Aldrich. All chemicals were used without
peptoid, as illustrated in Figure 4F, which displays a film further purification.
morphology intermediate between that of the pure lipid
mixture (Figure 4D) and of the film spiked with SP-C Peptide and Peptoid Synthesis
An SP-C peptide with a sequence of amino acids modified frompeptide (Figure 4E). The change in morphology provided
the natural sequence for improved stability of -helical secondaryby the SP-C peptoid, relative to that of the lipid mixture,
structure [37] was made by solid-phase synthesis on an ABI 433Asignals an increased fluidity of the film. This similarity
automated peptide synthesizer using standard Fmoc chemistry. The
in the action of the SP-C peptoid on the surfactant film peptoid 22-mer was also synthesized on the 433A on solid support
to the peptide’s behavior provides evidence that the (Rink amide resin) via the submonomer method [52] with Boc protec-
tion of NLys [53] and PMC protection of NArg [54] groups duringpeptoid has a substantial biomimetic interaction with
the synthesis. When the synthesis was complete, peptoid oligomersthe phospholipids. Taken together, the CD, PBS, LWSB,
were cleaved from the resin with 95% TFA/water along with neces-and FM results all suggest that the peptoid analog cap-
sary protecting group scavengers and HPLC purified using a lineartures the essential structural and surface-active proper-
gradient of 25%–100% solvent B in solvent A over 50 min (solvent
ties of lung surfactant protein C. A, 0.1% TFA in water [v/v]; solvent B, 0.1% TFA in isopropanol [v/v]).
The final purity of both compounds was confirmed by analytical
reversed-phased HPLC to be 97%. MALDI-TOF mass spectrome-
try confirmed the molar masses of the purified compounds to beSignificance
correct (SP-C peptide, 3803 Da; SP-C peptoid, 3309 Da).
We have designed a peptoid-based SP-C mimic that,
Circular Dichroismwhen integrated into a lipid film, holds promise as a
Peptide and peptoid samples were prepared in propanol:1% aceticbiomimetic lung surfactant replacement for the treat-
acid (4:1, v/v) solution at a 60 M concentration. CD was carried out
ment of RDS in premature infants and potentially at room temperature on a Jasco J-715 instrument using a cylindrical
adults as well. Oligopeptoids with -chiral side chains quartz cuvette (Hellma, Plainview, NY). Spectra shown represent
the average of 40 data accumulations.offer several advantages for mimicry of SP-C, includ-
ing their unusual stability in a helical secondary struc-
Molecular Modelingture and their strong resistance to aggregation [9, 10,
A model of the helical SP-C peptoid was created using Insight II51]. In addition, peptoid oligomers have been shown to
(Accelrys, San Diego, CA) by inputting the central backbone dihedralbe protease resistant and are easily and inexpensively
angles of a closely related, helical peptoid pentamer structure com-
produced by solid-phase synthesis [7, 52], traits that prised of para-substituted Nspe monomers previously solved in
are critical for the successful development of a pepti- methanol solution by 2D NMR [38].
domimetic therapeutic agent.
The structured, amphipathic peptoid analog that we Pulsating Bubble Surfactometry
Static and dynamic characterization of surfactant film propertieshave created for biological mimicry of surfactant pro-
was performed on a pulsating bubble surfactometer (PBS) (Generaltein C, comprised of 22 monomers of seven different
Transco, Largo, FL). The lipid mixture (DPPC:POPG:PA, 68:22:9 [bytypes, is one of the longest and most complex nonnat-
weight]) was dissolved in chloroform [41] to a total phospholipid
ural peptidomimetic oligomers yet evaluated as a pro- concentration of 1 mg/ml. The lipid mixture was then spiked with
tein replacement. It combines three important fea- 10% (w/w) SP-C mimic. The sample was prepared in an Eppendorf
tube, dried under vacuum, and resuspended in an aqueous solutiontures: a specific, biomimetic sequence of monomers,
of 0.15 M NaCl and 5 mM CaCl2. Measurements on the PBS wereprecise chain length, and mimicry of a biological (heli-
made at 37C and with a bulk surfactant concentration of 1 mg/ml.cal) secondary structure. The results presented here
When a constant, equilibrium surface tension had been obtainedindicate that peptoids and other nonnatural oligomers
after initial surfactant adsorption to the interface, surface tension
have excellent potential to be developed for therapeu- versus interfacial area data were gathered, with compression and
tic applications, particularly where the goal is to mimic expansion loops obtained by cycling the bubble size at a frequency
of 20 cycles/min.bioactive protein domains that interact with lipid bi-
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